Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
In the latest session, BioNTech SE ADR (NASDAQ: BNTX) closed at $117.14 down -2.24% from its previous closing price of $119.82. In other words, the price has decreased by -$2.24 from its previous closing price. On the day, 1.03 million shares were traded. BNTX stock price reached its highest trading level at $123.19 during the session, while it also had its lowest trading level at $115.02.
Ratios:
For a deeper understanding of BioNTech SE ADR’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.51 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 18.99. For the most recent quarter (mrq), Quick Ratio is recorded 7.21 and its Current Ratio is at 7.33. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Truist on January 10, 2025, initiated with a Buy rating and assigned the stock a target price of $172.
On December 11, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $170.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 13 ’24 when ATHOS KG bought 4,983 shares for $120.69 per share.
ATHOS KG bought 22,450 shares of BNTX for $2,623,283 on Dec 11 ’24. On Dec 09 ’24, another insider, ATHOS KG, who serves as the 10% Owner of the company, bought 53,716 shares for $121.72 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BNTX now has a Market Capitalization of 28083142656 and an Enterprise Value of 11617514496. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.51 while its Price-to-Book (P/B) ratio in mrq is 1.32. Its current Enterprise Value per Revenue stands at 3.821 whereas that against EBITDA is -42.322.
Stock Price History:
The Beta on a monthly basis for BNTX is 0.29, which has changed by 0.26059973 over the last 52 weeks, in comparison to a change of 0.2000997 over the same period for the S&P500. Over the past 52 weeks, BNTX has reached a high of $131.49, while it has fallen to a 52-week low of $76.53. The 50-Day Moving Average of the stock is 0.21%, while the 200-Day Moving Average is calculated to be 14.87%.
Shares Statistics:
For the past three months, BNTX has traded an average of 832.07K shares per day and 714630 over the past ten days. A total of 239.74M shares are outstanding, with a floating share count of 239.44M. Insiders hold about 0.13% of the company’s shares, while institutions hold 19.47% stake in the company. Shares short for BNTX as of 1736899200 were 2642082 with a Short Ratio of 3.18, compared to 1734048000 on 2327232. Therefore, it implies a Short% of Shares Outstanding of 2642082 and a Short% of Float of 5.29.
Earnings Estimates
BioNTech SE ADR (BNTX) is currently under the scrutiny of 14.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$2.07, with high estimates of -$1.23 and low estimates of -$2.99.
Analysts are recommending an EPS of between -$1.29 and -$5.76 for the fiscal current year, implying an average EPS of -$3.29. EPS for the following year is -$3.42, with 20.0 analysts recommending between -$0.06 and -$7.92.
Revenue Estimates
A total of 12 analysts believe the company’s revenue will be $1.16B this quarter.It ranges from a high estimate of $1.75B to a low estimate of $866.38M. As of the current estimate, BioNTech SE ADR’s year-ago sales were $1.48BFor the next quarter, 12 analysts are estimating revenue of $192.32M. There is a high estimate of $242.9M for the next quarter, whereas the lowest estimate is $145M.
A total of 19 analysts have provided revenue estimates for BNTX’s current fiscal year. The highest revenue estimate was $2.86B, while the lowest revenue estimate was $2.4B, resulting in an average revenue estimate of $2.65B. In the same quarter a year ago, actual revenue was $3.82BBased on 19 analysts’ estimates, the company’s revenue will be $2.55B in the next fiscal year. The high estimate is $3.37B and the low estimate is $1.81B.
